A Study to Evaluate the Efficacy and Safety of AD-224
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.
Also called NCT06291207
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 254 participants
- Sponsor
- Registry
-
NCT06291207
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06291207. Randomized; double masking; primary purpose treatment. Start 2024-04-15 (actual); primary completion 2025-04-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of AD-224
- Condition
- Hypertension,Essential
- Intervention (Drug)
- AD-224A
- Intervention (Drug)
- AD-224B
- Intervention (Drug)
- AD-224C
- Intervention (Drug)
- Placebo of AD-224A
- Intervention (Drug)
- Placebo of AD-224B
- Intervention (Drug)
- Placebo of AD-224C
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct06291207- Content hash
2adb7d140fe998e0675f87141d7934724b483fb36fe561148efc57a166aa29b9